Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis.
10.3350/kjhep.2010.16.4.376
- Author:
Moon Young KIM
1
;
Soon Koo BAIK
;
Chan Sik WON
;
Hong Jun PARK
;
Hyo Keun JEON
;
Hyun Il HONG
;
Jae Woo KIM
;
Hyun Soo KIM
;
Sang Ok KWON
;
Jang Young KIM
;
Byung Su YOO
;
Seung Hwan LEE
Author Information
1. Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. baiksk@medimail.co.kr
- Publication Type:Original Article ; Controlled Clinical Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Cirrhotic cardiomyopathy;
Dobutamine stress echocardiography;
Liver cirrhosis
- MeSH:
Adrenergic beta-1 Receptor Agonists/*diagnostic use;
Adult;
Aged;
Dobutamine/*diagnostic use;
Echocardiography, Stress;
Female;
Heart Diseases/complications/physiopathology/*ultrasonography;
Humans;
Liver Cirrhosis/*complications/physiopathology;
Male;
Middle Aged;
Receptors, Adrenergic, beta-1/chemistry/metabolism;
Severity of Illness Index;
Ventricular Function, Left/physiology
- From:The Korean Journal of Hepatology
2010;16(4):376-382
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: The blunted ventricular systolic and diastolic contractile responses to physical and pharmacological stress in cirrhosis are termed cirrhotic cardiomyopathy (CCM). CCM has been known to involve multiple defects in the beta-adrenergic signaling pathway. The aim of this study was to determine whether cirrhotic patients have blunted cardiac responses to catecholamine stimulation through dobutamine stress echocardiography (DSE). METHODS: Seventy-one cirrhotic patients with normal left ventricular (LV) chamber size and ejection fraction were enrolled. The LV systolic and diastolic functions were evaluated by two-dimensional and Doppler echocardiography at rest and during peak dobutamine infusion (40 microg/kg/min). An abnormal response was defined as a decrease of less than 10% in LV end-diastolic volume, a decrease of less than 20% in end-systolic volume, and an increase of less than 10% in LV ejection fraction (EF) at peak dobutamine infusion, based on previously used criteria. The early/late diastolic flow (E/A) ratio and diastolic parameters were also measured. RESULTS: A blunted LV response to dobutamine was observed in 18 of 71 cirrhotic patients (25.4%). The baseline EF was significantly higher in 18 patients with a blunted DSE response than that of those with a normal DSE response (P<0.05). The baseline and peak E/A ratios, which are common diastolic dysfunction markers, were higher in the cirrhosis group than in the control group (P<0.001). No adverse events associated with DSE were observed. CONCLUSIONS: Blunted cardiac responses to dobutamine stimulation, which are implicated in defects in the beta-adrenergic signaling pathway, might contribute to the pathogenesis of CCM in patients with cirrhosis.
